ERBB2 and breast carcinoma: As an initial validation, we tested a subset of the predictions in well-characterized breast cancer cell lines, two unseen by the models and two previously seen (HER2 positive: SK-BR-3, BT-474 and two triple negative: SUM159, HCC1806).